Triterpenoids from Ganoderma lucidum inhibit the activationof EBV antigens as telomerase inhibitors

Experimental and Therapeutic Medicine

Volumn 14, Issue 4, 2017, Pages 3273-3278

  Zheng, Dong Shu ^a   Chen, Liang Shu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Epstein Barr virus antigens; Ganoderma lucidum; Nasopharyngeal carcinoma; Physicochemical properties; Telomerase inhibitor; Triternepoids

Indexed keywords

EARLY ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GANODERIC ACID A; GANODERIC ACID B; GANODERMANONDIOL; GANODERMANONTRIOL; GANODEROL B; TELOMERASE INHIBITOR; TRITERPENOID; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN;

ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG ISOLATION; ENZYME INHIBITION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS INFECTION; GANODERMA LUCIDUM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOLECULAR DOCKING; MOLECULAR MODEL; MTT ASSAY; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYTOCHEMISTRY; POLYMERASE CHAIN REACTION; SPECTROSCOPY; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

EID: 85028583292     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2017.4883     Document Type: Article

References (39)

1. Liao K, Xia B, Zhuang QY, Hou MJ, Zhang YJ, Luo B, Qiu Y, Gao YF, Li XJ, Chen HF, et al: Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-κB/COX-2 pathway. Theranostics 5: 302-321, 2015.
2. Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet 365: 2041-2054, 2005.
3. Hildesheim A and Levine PH: Etiology of nasopharyngeal carcinoma: A review. Epidemiol Rev 15: 466-485, 1993.
4. Petersson F: Nasopharyngeal carcinoma: A review. Semin Diagn Pathol 32: 54-73, 2015.
5. Liu Q, Guan X, Lv J, Li X, Wang Y and Li L: Limb-bud and heart (LBH) functions as a tumor suppressor of nasopharyngeal carcinoma by inducing G1/S cell cycle arrest. Sci Rep 5: 7626, 2015.
6. Stoker SD, Novalić Z, Wildeman MA, Huitema AD, Verkuijlen SA, Juwana H, Greijer AE, Tan IB, Middeldorp JM and de Boer JP: Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. J Cancer Res Clin Oncol 141: 1845-1857, 2015.
7. Bellon M and Nicot C: Regulation of telomerase and telomeres: Human tumor viruses take control. J Natl Cancer Inst 100: 98-108, 2008.
8. Kamranvar SA, Chen X and Masucci MG: Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus. Oncogene 32: 5522-5530, 2013.
9. Rac J, Haas F, Schumacher A, Middeldorp JM, Delecluse HJ, Speck RF, Bernasconi M and Nadal D: Telomerase activity impacts on Epstein-Barr virus infection of AGS cells. PLoS One 10: e0123645, 2015.
10. Feldser DM and Greider CW: Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11: 461-469, 2007.
11. Chen Z, Shao M, Chen X, Yu W, Wu Z, Ding J, Yu D, Wang P, Wang J, Wang L, et al (eds): Ganoderma. In: Zhongguo Yao Dian. Vol 1. 2015 edition. China Medical Science Press, Beijing, pp 188-189, 2015.
12. Liu DZ, Zhu YQ, Li XF, Shan WG and Gao PF: New triterpenoids from the fruiting bodies of Ganoderma lucidum and their bioactivities. Chem Biodivers 11: 982-986, 2014.
13. Luo Q, Wang XL, Di L, Yan YM, Lu Q, Yang XH, Hu DB and Cheng YX: Isolation and identification of renoprotective substances from the mushroom Ganoderma lucidum. Tetrahedron 71: 840-845, 2015.
14. Lv GP, Zhao J, Duan JA, Tang YP and Li SP: Comparison of sterols and fatty acids in two species of Ganoderma. Chem Cent J 6: 10, 2012.
15. Chen Y, Bicker W, Wu J, Xie M and Lindner W: Simultaneous determination of 16 nucleosides and nucleobases by hydrophilic interaction chromatography and its application to the quality evaluation of Ganoderma. J Agric Food Chem 60: 4243-4252, 2012.
16. Wang XF, Yan YM, Wang XL, Ma XJ, Fu XY and Cheng YX: Two new compounds from Ganoderma lucidum. J Asian Nat Prod Res 17: 329-332, 2015.
17. Hasnat MA, Pervin M, Cha KM, Kim SK and Lim BO: Anti-inflammatory activity on mice of extract of Ganoderma lucidum grown on rice via modulation of MAPK and NF-κB pathways. Phytochemistry 114: 125-136, 2015.
18. Pan D, Wang L, Chen C, Hu B and Zhou P: Isolation and characterization of a hyperbranched proteoglycan from Ganoderma lucidum for anti-diabetes. Carbohydr Polym 117: 106-114, 2015.
19. Zhang W, Zhang Q, Deng W, Li Y, Xing G, Shi X and Du Y: Neuroprotective effect of pretreatment with Ganoderma lucidum in cerebral ischemia/reperfusion injury in rat hippocampus. Neural Regen Res 9: 1446-1452, 2014.
20. Dai S, Liu J, Sun X and Wang N: Ganoderma lucidum inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43. BMC Complement Altern Med 14: 434, 2014.
21. Chinese Society of Radiation Oncology of Chinese Medical Association: Clinical diagnostic staging criteria of nasopharyngeal carcinoma. New Med 28: 672, 1997.
22. Tanaka R, Ishikawa Y, Minami T, Minoura K, Tokuda H and Mateunaga S: Two new anti-tumor promoting serratane-type triterpenoids from the stem bark of Picea jezoensis var. jezoensis. Planta Med 69: 1041-1047, 2003.
23. Kapadia GJ, Azuine MA, Tokuda H, Hang E, Mukainaka T, Nishino H and Sridhar R: Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation. Pharmacol Res 45: 213-220, 2002.
24. Murakami A, Ohgashi H and Koshimizu K: Anti-tumor promotion with food phytochemicals: A strategy for cancer chemoprevention. Biosci Biotechnol Biochem 60: 1-8, 1996.
25. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
26. Zhang XM, Qiu M, Sun J, Zhang YB, Yang YS, Wang XL, Tang JF and Zhu HL: Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents. Bioorg Med Chem 19: 6518-6524, 2011.
27. Damu GL, Cui SF, Peng XM, Wen QM, Cai GX and Zhou CH: Synthesis and bioactive evaluation of a novel series of coumarinazoles. Bioorg Med Chem Lett 24: 3605-3608, 2014.
28. Caron G and Ermondi G: Molecular descriptors for polarity: The need for going beyond polar surface area. Future Med Chem, 2016.
29. Arisawa M, Fujita A, Morita N, Hayashi T, Shimizu M, Kikuchi T, Kadota S and Tezuka Y: Revision of 1H-and 13C-nmr assignments of lanostanoids from Ganoderma lucidum by 2D-nmr studies. J Nat Prod 51: 54-59, 1988.
30. Fujita A, Arisawa M, Saga M, Hayashi T and Morita N: Two new lanostanoids from Ganoderma lucidum. J Nat Prod 49: 1122-1125, 1986.
31. Kubota T, Asaka Y, Miura I and Mori H: Structures of ganoderic acid A and B, two new lanostane type bitter triterpenes from Ganoderma lucidum (FR.) KARST. Helv Chim Acta 65: 611-619, 1982.
32. Klupp NL, Kiat H, Bensoussan A, Steiner GZ and Chang DH: A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep 6: 29540, 2016.
33. Shao Y, Qiao L, Wu L, Sun X, Zhu D, Yang G, Zhang X, Mao X, Chen W, Liang W, et al: Structure identification and anti-cancer pharmacological prediction of triterpenes from Ganoderma lucidum. Molecules 21: pii: E678, 2016.
34. Gill BS, Kumar S and Navgeet D: Triterpenes in cancer: Significance and their influence. Mol Biol Rep 43: 881-896, 2016.
35. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232, 2006.
36. Manosroi A, Jantrawut P, Ogihara E, Yamamoto A, Fukatsu M, Yasukawa K, Tokuda H, Suzuki N, Manosroi J and Akihisa T: Biological activities of phenolic compounds and triterpenoids from the galls of Terminalia chebula. Chem Biodivers 10: 1448-1463, 2013.
37. Liu S, Li H, Chen L, Yang L, Li L, Tao Y, Li W, Li Z, Liu H, Tang M, et al: (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells. Carcinogenesis 34: 627-637, 2013.
38. Tauchi T, Shin-ya K, Sashida G, Sumi M, Okabe S, Ohyashiki JH and Ohyashiki K: Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: In vitro and in vivo studies in acute leukemia. Oncogene 25: 5719-5725, 2006.
39. Ding L, Li L, Yang J, Zhou S, Li W, Tang M, Shi Y, Yi W and Cao Y: Latent membrane protein 1 encoded by Epstein-Barr virus induces telomerase activity via p16INK4A/Rb/E2F1 and JNK signaling pathways. J Med Virol 79: 1153-1163,2007.